CVS Health Corp

CVS Health’s new TrumpRx partnership, biosimilar swaps, and veteran‑access plan show how the pharmacy giant is reshaping drug pricing, cutting costs and boosting competition while facing regulatory scrutiny and investor pressure.

CVS Health’s new $91 target from Bernstein shows bullish outlook amid insider‑trading probe—explore how its diversified pharmacy‑benefit model drives future growth.

CVS Health’s January 10 earnings call will reveal 2025 guidance, revenue trends, cost‑cutting plans and digital‑health strategy, guiding investors and customers alike.

CVS Health’s latest share‑holding shift signals investors eyeing PBM, specialty‑drug, and digital‑pharmacy trends amid rising competition and regulatory scrutiny.

CVS Health’s Q3 earnings beat expectations with record PBM revenue, yet a tragic store shooting highlights rising security risks that could impact its future growth and reputation.

CVS Health’s Brooklyn store launch and Dec. 9 Investor Day aim to boost retail reach and reassure investors amid rising drug‑pricing scrutiny and policy uncertainty.

CVS Health’s $5.7B goodwill write‑down, $3 M philanthropy boost, and UBS‑raised target raise questions about its high 217.4 P/E—investors must weigh social gains against deep valuation gaps.

CVS Health Corp is a key player in the weight loss drug market and the broader healthcare sector, with a strong financial foundation and strategic market positioning.

CVS Health Corp has successfully reopened a damaged store, highlighting its commitment to community service, despite facing short-term market fluctuations and regulatory challenges in the healthcare sector.

CVS Health Corp. reports strong Q1 performance, exceeding expectations and raising its 2025 outlook, driven by improving Medicare business and strategic decisions.